Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

Kosiborod, Mikhail; Cavender, Matthew A.; Fu, Alex Z.; Wilding, John P.; Khunti, Kamlesh; Holl, Reinhard; Norhammar, Anna; Birkeland, Kare I.; Jorgensen, Marit Eika; Thuresson, Marcus; Arya, Niki; Bodegard, Johan; Hammar, Niklas; Fenici, Peter; CVD-REAL Investigators Study Grp

Erstveröffentlichung

2017

Metadata only
Search for full text

Wissenschaftlicher Artikel

Autoren

Kosiborod, Mikhail

Cavender, Matthew A.

Fu, Alex Z.

Wilding, John P.

Khunti, Kamlesh

et al.

Fakultäten

Medizinische Fakultät

Institutionen

Institut für Epidemiologie und Medizinische Biometrie

Erschienen in

Circulation ; 136 (2017), 3. - S. 249+. - ISSN 0009-7322. - eISSN 1524-4539

Link zur Veröffentlichung

https://dx.doi.org/10.1161/CIRCULATIONAHA.117.029190

Förderinformationen

AstraZeneca

Schlagwörter

canagliflozin; dapagliflozin; death; diabetes mellitus; empagliflozin; heart failure; sodium glucose transporter 2; diabetes-mellitus; mortality; association; metaanalysis; prevalence; mechanisms; diagnosis; accuracy; register; disease

DDC-Sachgruppe

DDC 610 / Medicine & health

Metadata

Zur Langanzeige